News
LEXINGTON, KY. (Oct. 27, 2020) — A $2.9 million grant from the National Institutes of Health (NIH) is supporting a multidisciplinary team of University of Kentucky researchers in continuing their work to find therapeutic strategies to resolve neurovascular inflammation and repair blood-brain barrier dysfunction in epilepsy.
LEXINGTON, Ky. (Nov. 2, 2020) — In celebration of National Alzheimer’s Disease Awareness Month and National Family Caregiver’s Month, from Wednesday, Nov. 4 to Friday, Nov. 6, the William T. Young Library will shine purple to show the University of Kentucky's commitment to a world without Alzheimer's disease and to commemorate the important work done by caregivers.
Scientific Session
Monday, November 9, 2020
9:50 am - 2:00 pm via Zoom
Register Here
LEXINGTON, Ky. (Aug. 25, 2020) — Working with their colleagues at the University of Pennsylvania, researchers at the University of Kentucky have found that they can differentiate between subtypes of dementia inducing brain disease.
LEXINGTON, Ky. (Aug. 25, 2020) — Research looking at a possible new therapeutic approach for Alzheimer’s disease was recently published in the Journal of Neuroinflammation.
The Lexington Walk to End Alzheimer's is Saturday, September 12th so wear purple, get out & walk around town!
To join our team, click here!
The COVID-19 pandemic has impacted research, outcomes, long-term care and disparities related to Alzheimer’s disease and other dementias, according to presenters at the Alzheimer’s Association International Conference 2020.
Regarding its effects on research, Gregory Jicha, MD, PhD, chair of the Alzheimer’s Association Clinical Trials Advancement and Methods professional interest area, highlighted steps to safely conduct Alzheimer’s disease-related studies in the current pandemic environment.
Complete the Race anytime between Friday, August 14 and Saturday, August 29, 2020 for the Virtual Morning Light 5k to help raise money for UK Sanders-Brown Center on Aging!
Race fee includes race t-shirt. Medals will be awarded for top performers in each age category.
$25 for Early Bird registration until July 31st.
$30 for registration starting August 1st.
To register, click here.
LEXINGTON, Ky. (July 30, 2020) —The COVID-19 pandemic brought many things to a screeching halt and continues to impact our daily lives. However, important research at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) is continuing under extreme caution and deep dedication.
“It can’t wait,” said Dr. Greg Jicha, a neurologist at SBCoA.
LEXINGTON, Ky. (July 29, 2020) — Alzheimer’s disease (AD) is the most common form of dementia among the elderly and currently there is no cure for the disease. The hallmarks of AD are the Aβ plaques and tau tangles found throughout the patient’s brain. For the past several decades, much of the work to find a treatment for AD has been focused on eliminating those dreaded Aβ plaques, by assuming that memory could be restored by removing the plaques.
LEXINGTON, Ky. (July 17, 2020) — Researchers at the University of Kentucky Sanders-Brown Center on Aging (SBCoA) recently screened the first participant in the world for what is known as the AHEAD 3-45 study. This work is looking at a study medication, BAN2401, to determine if it can help prevent worsening memory and thinking among individuals who might be at risk for future decline. They are hoping this study finds that BAN2401 does just that and will ultimately help prevent Alzheimer’s disease.
LEXINGTON, Ky. (July 8, 2020) - A grant recently received by Maj-Linda B. Selenica, assistant professor at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA), is helping further collaborative research efforts. The $125,000 grant comes from The CART Fund. CART (Coins for Alzheimer’s Research Trust) is a grassroots effort by Rotary Club members throughout the country to provide cutting edge research to help find a cure for Alzheimer’s.
The University of Kentucky’s Sanders-Brown Center on Aging has been a leader in Alzheimer’s Disease related research for many years. The success seen at Sanders-Brown can be directly attributed to the people within the center.
“UK is fantastic at many things, but when it comes to driving the science and the search for cures for diseases like Alzheimer’s, we are second to none,” said Dr. Greg Jicha.
Linda J. Van Eldik, director of the Sanders-Brown Center on Aging at the University of Kentucky, co-authored a paper reporting the first human clinical study of a drug candidate that suppresses injury and disease-induced inflammation of the brain.
An international group of experts led by Dr. Peter Nelson, a neuropathologist at the University of Kentucky Sanders-Brown Center on Aging, is being recognized as one of the top science stories of 2019 by Discover Magazine.
More than 70,000 Kentuckians are living with Alzheimer's disease, which likely means that you know someone whose life has been touched — directly or indirectly — by dementia. And since that number is expected to rise to more than 85,000 in the next five years or so, Alzheimer's will likely hit closer to home for many of us.
At the University of Kentucky, multiple innovative biospecimen resources are available to assist research. A video produced by the UK Center for Clinical and Translational Science (CCTS) highlights the biospecimen resources offered by the CCTS, the UK Markey Cancer Center, the UK Gill Heart Institute, and the Alzheimer’s Disease Center at the Sanders-Brown Center on Aging.